High refill-adherence to adalimumab is associated with low disease activity in patients with inflammatory bowel disease.
Esma H SanAngelique EgbertsCaroline W Th van Dijck-van BoetzelaerRachel L WestErwin C VasbinderPublished in: European journal of clinical pharmacology (2024)
High refill-adherence to adalimumab therapy was associated with less active disease in IBD patients. Our results confirm the relevance of good adherence to adalimumab for achieving optimal treatment results, which may limit the need for switching to more expensive biologics.
Keyphrases
- rheumatoid arthritis
- disease activity
- juvenile idiopathic arthritis
- patients with inflammatory bowel disease
- systemic lupus erythematosus
- end stage renal disease
- rheumatoid arthritis patients
- ulcerative colitis
- ankylosing spondylitis
- newly diagnosed
- ejection fraction
- chronic kidney disease
- hidradenitis suppurativa
- prognostic factors
- glycemic control
- stem cells
- adipose tissue
- bone marrow
- skeletal muscle
- mesenchymal stem cells
- cell therapy